Keywords: Bayer, Xarelto, Johnson & Johnson, Warfarin, Atrial fibrilation, Stroke reduction, Sales potential, Boehringer Ingelheim, Pradaxa, Systemiuc embolism
Landmark double-blind ROCKET AF study shows Bayer/J&J’s Xarelto is better than warfarin
Article | 16 November 2010
German drug major Bayer (BAY: DE) yesterday announced the eagerly-awaited results from the pivotal, double-blind Phase III, ROCKET AF trial, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
